治疗疗效得分:在新辅助性乳腺癌试验中,更好的替代手臂生存差异?
Rachel Jaber Chehayeb1, Adriana Kahn2, Lajos Pusztai2
1Yale School of Medicine, New Haven, CT 06511, USA.
Future oncology (London, England)
|September 28, 2023
概括
乳腺癌的新辅助化疗改善了生存率,但病理完整反应 (pCR) 率有所不同. 一个新的残留癌症负担得分更好地反映了治疗疗效和生存率的改善,而不是单独的pCR.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 新辅助化疗是II-III期乳腺癌的标准治疗方法.
- 新辅助化疗后的病理完整反应 (pCR) 与改善的生存率相关.
- 然而,试验中的pCR速率差异并不总是预测生存率的改善.
研究的目的:
- 评估pCR在评估乳腺癌治疗疗效方面的局限性.
- 引入和验证残留癌症负担 (RCB) 评分作为一种更准确的病理反应衡量标准.
- 开发一种新的统计指标,即治疗疗效得分,作为改善生存率的优越替代品.
主要方法:
- 利用先前开发的残留癌症负担 (RCB) 评分,这是病理反应的连续测量.
- 在治疗手臂之间比较RCB得分的分布,以评估治疗疗效.
- 开发并验证了一种新的治疗疗效评分.
主要成果:
- RCB得分提供了比pCR率差异更准确的治疗疗效的反映.
- 新开发的治疗疗效得分显示,与pCR率差异相比,与生存率改善的相关性更强.
- RCB得分分析捕捉了残留疾病患者的治疗效应,而pCR没有.
结论:
- 其余癌症负担得分比pCR更具信息性,用于评估乳腺癌中新辅助化疗的疗效.
- 治疗疗效得分显示,作为预测试验手臂水平生存益处的优越代用品,具有前途.
- 这些指标提供了对治疗反应及其对患者结果的影响更细致的了解.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
Comparing the Survival Analysis of Two or More Groups
218
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
218
Kaplan-Meier Approach
178
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
178
Survival Curves
192
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
192
Actuarial Approach
96
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
96
